Gary P Jeffrey
Overview
Explore the profile of Gary P Jeffrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ormiston W, Samuelson S, Van Wyk M, Calzadilla-Bertot L, Smith B, Garas G, et al.
J Med Imaging Radiat Oncol
. 2025 Feb;
PMID: 39913851
Introduction: Portal vein tumour thrombus (PVTT) is a common complication of hepatocellular carcinoma (HCC) and has a poor prognosis. Selective internal radiation therapy (SIRT) with Yttrium-90 (Y90) microspheres is a...
2.
Jayabalan D, Huang Y, Calzadilla-Bertot L, Adams L, Cheng W, Hazeldine S, et al.
J Gastroenterol Hepatol
. 2024 Dec;
40(3):731-740.
PMID: 39686812
Background And Aim: Prognosis in autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) has historically been poor. This multicenter retrospective cohort study investigated the natural history...
3.
Jayabalan D, Huang Y, Calzadilla-Bertot L, Janjua M, De Boer B, Joseph J, et al.
World J Hepatol
. 2024 Oct;
16(9):1269-1277.
PMID: 39351512
Background: Survival in patients with autoimmune liver disease overlap syndromes (AILDOS) compared to those with single autoimmune liver disease is unclear. Aim: To investigate the survival of patients with AILDOS...
4.
Calzadilla-Bertot L, Jeffrey A, Jeffrey G
Hepatology
. 2024 Feb;
79(6):E153-E154.
PMID: 38349675
No abstract available.
5.
Fink M, Gow P, McCaughan G, Hodgkinson P, Chen J, McCall J, et al.
Clin Transplant
. 2023 Dec;
38(1):e15203.
PMID: 38088459
Patients with high model for end-stage liver disease (MELD) scores waiting for liver transplantation in Australia and New Zealand (ANZ) have had limited access to deceased donor livers and therefore...
6.
7.
Properzi C, Adams L, Lo J, Sherriff J, Jeffrey G, OSullivan T
Nutrients
. 2023 Jun;
15(12).
PMID: 37375573
We aimed to compare the dietary intakes of Australian patients with non-alcoholic fatty liver disease (NAFLD) to general Australian population intake data and determine whether the intake of any nutrient...
8.
Wang Z, Jeffrey G, Huang Y, De Boer B, Garas G, Wallace M, et al.
Hepatol Int
. 2023 Jun;
17(5):1162-1169.
PMID: 37358741
Background And Aims: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate...
9.
Calzadilla-Bertot L, Jeffrey G, Wang Z, Huang Y, Garas G, Wallace M, et al.
Hepatology
. 2023 Mar;
78(4):1240-1251.
PMID: 36994693
Background And Aims: Management of NAFLD involves noninvasive prediction of fibrosis, which is a surrogate for patient outcomes. We aimed to develop and validate a model predictive of liver-related events...
10.
Bertot L, Jeffrey G, De Boer B, Wang Z, Huang Y, Garas G, et al.
Dig Dis Sci
. 2023 Mar;
68(6):2757-2767.
PMID: 36947289
Background: Non-invasive tests are widely used to diagnose fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), however, the optimal method remains unclear. We compared the accuracy of simple serum...